Top Markets
#1 Siren Siren +43.80%
#2 Seeker Seeker +24.90%
#3 Full Moon Full Moon +19.61%
#4 Wrapped NXM Wrapped NXM +12.15%
#5 Zora Zora +10.73%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.64%
#7 VVS Finance VVS Finance +9.99%
#8 Cryptopia Cryptopia +9.26%
#9 Axelar Axelar +8.27%
#10 Helium Helium +8.16%
Coin of the day
Siren Siren
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN
Classificação em ações #12014
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Preço da ação
$13.34
Última sincronização: 2026-08-28
Valor de mercado
$629.93M
Variação (1 dia)
-0.84%
Variação (1 ano)
177.26%
País
GB
Negociar Silence Therapeutics plc (SLN)

Categoria

Healthcare
Histórico de preços das ações de Silence Therapeutics plc (SLN)
Preço de fecho mais alto: $13.70 em 2026-08-01

Preço de fecho mais baixo: $18.26 em 2020-09-01
Histórico de preços das ações da Silence Therapeutics plc de 2020 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 10.68%
2025 -10.61%
2024 -54.38%
2023 3.22%
2022 -37.25%
2021 25.25%
2020 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.36 -12.82%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH